Who we are

Unlocking data's complexity to realise the promise of precision oncology

Concr is a value-driven techbio company, applying statistical learning and advanced modelling adopted from astrophysics to aid in precision treatment of cancer patients

Serving patients as individuals

Our science is built to serve patients in a way that is deeply useful to each and every individual.

Breaking down barriers

Information silos cause death. We break down existing information technology barriers and harness genomic knowledge to prevent needless suffering.

We integrate knowledge that sits apart and open access to this knowledge for the benefit of all.

Giving equity of access to health

Equity of access to health is a human right. Our work builds the ability to deliver and access smarter healthcare choices to create healthier futures for individuals.

If you are going to do something new, you are by definition unqualified to do it

- Francis Crick

Innovating to solve

We embrace innovation to change the status quo for the better. Problems, failures, challenges are the starting point to making a difference.

Collaboration not competition

No one group is smarter than all. We embrace openness and collaboration in pursuit of our common goal.

We are a driven team of individuals who deeply care about the value of human life, believe in the power of science and work tirelessly to make our vision a reality

Platform Solutions

Leadership team

Tim Sparey

Non-Executive Chair

Dr Tim Sparey (PhD) is a successful, serial entrepreneur with extensive C-suite and board level experience in the pharmaceutical sector. He holds multiple executive and advisory positions for a number of successful and established biotech and therapeutics companies.

His transactional experience in fundraising and dealmaking is worth over $6bn. His previous experiences cover multiple therapeutic and technology areas including cancer, CNS, inflammation, ophthalmology and drug delivery in public and private companies including Novintum, Midatech, Q Chip, Proximagen and Merck & Co, where he helped build and sell companies and assets in different therapeutics areas. He has over 40 patents and publications.

LinkedIn profile

Andrew Biankin

Scientific Strategy Advisor

Prof Andrew Biankin (AO, FRSE, FMedSci) is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, and a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology and established the Glasgow Precision Oncology Laboratory which he directs.

He plays leadership roles in national and international consortia in cancer genomics and therapeutic development including the Chair of Precision-Panc and Executive Director of the International Cancer Genome Consortium. He has authored over 200 articles in major journals including seminal works on cancer, genomics and precision medicine.

As the Scientific Strategy Advisor to Concr, Andrew guides Concr's leadership and product teams in refining their strategy to maximise opportunities on the biopharma and translational fronts.

LinkedIn profile

Ronjon Nag

Investment Director

Prof Ronjon Nag (PhD) is an inventor and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine, becoming a Stanford Distinguished Careers Institute Fellow in 2016. He is a founder and advisor/board member of multiple start-ups. His companies have been sold to Apple, BlackBerry, and Motorola.

More recently he has worked on the intersection of AI and Biology. He has been awarded the Mountbatten Medal in the Royal Institution by the Institution of Engineering and Technology and has been the winner (as Chairman of Bounce Imaging) of the $1m Verizon Powerful Answers Award. He was awarded the 2021 IEEE-SCV Outstanding Engineer Award and the 2021 IEEE-USA Leader in Entrepreneurship Spirit Award.

LinkedIn profile

Irina Babina

Chief Executive Officer

Dr Irina Babina (PhD, MBA) leverages diverse research and innovation expertise to provide visionary leadership and strategic direction to Concr as its CEO. She brings a rounded knowledge and first-hand experience of developing healthcare innovations and bringing them to market through her tenures in academia, NHS, start-ups, pharma and venture capital.

A trained geneticist, Irina spent over 10 years as a cancer scientist, developing targeted breast and gastric cancer therapies at the Royal College of Surgeons in Ireland and the Institute of Cancer Research (London). Previously working across Imperial College and Imperial Healthcare NHS Trust, she focused on helping other researchers with the development of their ideas and healthcare innovations, aided by an MBA from Imperial Business School and venture capital work.

Over the last 17 years, Irina secured £103m in grant funding, delivered composite research programmes totalling >£110m, and assisted with the set-up of 5 and the successful exit of 2 MedTech start-ups.

LinkedIn profile

Nicholas Stern

Chief Financial Officer

Nicholas has over 18 years’ experience in finance, with significant expertise advising a wide variety of organisations, ranging from start-ups to large multinational organisations. After eight years in global restructuring, corporate finance and lead advisory at PwC, Nicholas transitioned his work towards board advisory. With significant experience working with venture and private equity-backed companies, he guides management teams that are seeking to build their businesses with a view to working towards a significant value realisation event.

Nicholas is a Fellow of the Association of Chartered Certified Accountants, having trained at Saffery Champness in London, and is also on the expert panel for Accelerate at Babraham. He has advised a number of biotech companies and large pharma on matters ranging from financial compliance to carve-out planning and restructuring. At Concr, Nicholas works closely with the management and leadership teams to develop and deliver on Concr’s financial objectives.

LinkedIn profile

Matthew Griffiths

Chief Technology Officer

Dr Matthew Griffiths (PhD) leads the development of Concr’s technology, managing the strategy, algorithmic development, model and data integration, and collaborations with computational research partners.

Matthew has extensive experience developing a wide range of novel computational methods to solve a range of problems, ranging from biophysical simulations of cells and molecular similarity algorithms to advanced Bayesian and Monte Carlo simulation algorithms.

LinkedIn profile

Uzma Asghar

Chief Scientific Officer

Dr Uzma Asghar (MBBS, MRCP, PhD) has dual roles as Chief Scientific Officer at Concr and a practising Consultant Medical Oncologist in the NHS (Royal Marsden Hospital and Croydon University Hospital) with a strong interest in breast cancer and other solid tumour types. She trained in North London (University College London, Royal Free Hospital and North Middlesex Hospital), completed her PhD at Breast Cancer Now, Institute of Cancer Research as a Doctor Avon Fellow and gained clinical trial experience at the NIHR UCLH Clinical Research Facility. 

In 2022, Uzma has been accepted into the NHS Clinical Entrepreneur Programme. As the CSO, Uzma’s mission is to apply Concr’s clever technology to solve scientific problems, help identify which cancer drugs people will respond to and bring new drugs to the clinic.

LinkedIn profile

Matt Foster

Chief Innovation Officer

Matt is a biomedical engineer with both biomedical research and engineering training. He has previously worked and published in roles at the forefront of computational modelling, in-vitro modelling, immunology, and project management.

As a co-founder of Concr, Matt helped define and shape the company mission, and as a former CEO, he was instrumental in building and steering the company to significant  milestones. In his role as the Chief Innovation Officer, Matt will continue to apply his innovative thinking to new applications of Concr technology. 

As his first start-up, Matt takes the most pride in developing and being part of an environment to learn from the Concr team, seeing them find purpose in the company mission. His passion is to realise the vision of patient-centred and fully accessible precision diagnostics in oncology.

LinkedIn profile

Emre Misirlioglu

Chief Operating Officer

As the generalist responsible for the smooth running of day-to-day activities, Emre embraces a versatile approach to leading the company operations at Concr. He is tasked with designing and implementing practical solutions for Concr’s key business objectives.

Together with the Executive Committee and alongside an expert team of advisors, Emre spearheads corporate development, quality management, regulatory compliance and GTM strategy implementation to deliver Concr's innovative solutions to market. With a clinical background and a commitment to elevating health and well-being at all levels, he is part of Concr’s translational efforts to connect cutting-edge technology with meaningful patient outcomes.

LinkedIn profile

Barney Plummer

Head of Product Development

With a background in physics, Barney leads the product development efforts at Concr with a hands-on approach. An expert in healthcare software development, he has vast experience in a variety of projects including AI/ML work, database performance profiling, and mobile app development.

His current responsibilities in UX/UI and software development coupled with his past experience in building products used by thousands of clinicians are put to good use in placing Concr's technology in the hands of its users.

LinkedIn profile

Tim Sparey

Non-Executive Chair

Dr Tim Sparey (PhD) is a successful, serial entrepreneur with extensive C-suite and board level experience in the pharmaceutical sector. He holds multiple executive and advisory positions for a number of successful and established biotech and therapeutics companies.

His transactional experience in fundraising and dealmaking is worth over $6bn. His previous experiences cover multiple therapeutic and technology areas including cancer, CNS, inflammation, ophthalmology and drug delivery in public and private companies including Novintum, Midatech, Q Chip, Proximagen and Merck & Co, where he helped build and sell companies and assets in different therapeutics areas. He has over 40 patents and publications.

Andrew Biankin

Scientific Strategy Advisor

Prof Andrew Biankin (AO, FRSE, FMedSci) is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, and a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology and established the Glasgow Precision Oncology Laboratory which he directs.

He plays leadership roles in national and international consortia in cancer genomics and therapeutic development including the Chair of Precision-Panc and Executive Director of the International Cancer Genome Consortium. He has authored over 200 articles in major journals including seminal works on cancer, genomics and precision medicine.

As the Scientific Strategy Advisor to Concr, Andrew guides Concr's leadership and product teams in refining their strategy to maximise opportunities on the biopharma and translational fronts.

Ronjon Nag

Investment Director

Prof Ronjon Nag (PhD) is an inventor and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine, becoming a Stanford Distinguished Careers Institute Fellow in 2016. He is a founder and advisor/board member of multiple start-ups. His companies have been sold to Apple, BlackBerry, and Motorola.

More recently he has worked on the intersection of AI and Biology. He has been awarded the Mountbatten Medal in the Royal Institution by the Institution of Engineering and Technology and has been the winner (as Chairman of Bounce Imaging) of the $1m Verizon Powerful Answers Award. He was awarded the 2021 IEEE-SCV Outstanding Engineer Award and the 2021 IEEE-USA Leader in Entrepreneurship Spirit Award.

Irina Babina

Chief Executive Officer

Dr Irina Babina (PhD, MBA) leverages diverse research and innovation expertise to provide visionary leadership and strategic direction to Concr as its CEO. She brings a rounded knowledge and first-hand experience of developing healthcare innovations and bringing them to market through her tenures in academia, NHS, start-ups, pharma and venture capital.

A trained geneticist, Irina spent over 10 years as a cancer scientist, developing targeted breast and gastric cancer therapies at the Royal College of Surgeons in Ireland and the Institute of Cancer Research (London). Previously working across Imperial College and Imperial Healthcare NHS Trust, she focused on helping other researchers with the development of their ideas and healthcare innovations, aided by an MBA from Imperial Business School and venture capital work.

Over the last 17 years, Irina secured £103m in grant funding, delivered composite research programmes totalling >£110m, and assisted with the set-up of 5 and the successful exit of 2 MedTech start-ups.

Nicholas Stern

Chief Financial Officer

Nicholas has over 18 years’ experience in finance, with significant expertise advising a wide variety of organisations, ranging from start-ups to large multinational organisations. After eight years in global restructuring, corporate finance and lead advisory at PwC, Nicholas transitioned his work towards board advisory. With significant experience working with venture and private equity-backed companies, he guides management teams that are seeking to build their businesses with a view to working towards a significant value realisation event.

Nicholas is a Fellow of the Association of Chartered Certified Accountants, having trained at Saffery Champness in London, and is also on the expert panel for Accelerate at Babraham. He has advised a number of biotech companies and large pharma on matters ranging from financial compliance to carve-out planning and restructuring. At Concr, Nicholas works closely with the management and leadership teams to develop and deliver on Concr’s financial objectives.

Matthew Griffiths

Chief Technology Officer

Dr Matthew Griffiths (PhD) leads the development of Concr’s technology, managing the strategy, algorithmic development, model and data integration, and collaborations with computational research partners.

Matthew has extensive experience developing a wide range of novel computational methods to solve a range of problems, ranging from biophysical simulations of cells and molecular similarity algorithms to advanced Bayesian and Monte Carlo simulation algorithms.

Uzma Asghar

Chief Scientific Officer

Dr Uzma Asghar (MBBS, MRCP, PhD) has dual roles as Chief Scientific Officer at Concr and a practising Consultant Medical Oncologist in the NHS (Royal Marsden Hospital and Croydon University Hospital) with a strong interest in breast cancer and other solid tumour types. She trained in North London (University College London, Royal Free Hospital and North Middlesex Hospital), completed her PhD at Breast Cancer Now, Institute of Cancer Research as a Doctor Avon Fellow and gained clinical trial experience at the NIHR UCLH Clinical Research Facility. 

In 2022, Uzma has been accepted into the NHS Clinical Entrepreneur Programme. As the CSO, Uzma’s mission is to apply Concr’s clever technology to solve scientific problems, help identify which cancer drugs people will respond to and bring new drugs to the clinic.

Matt Foster

Chief Innovation Officer

Matt is a biomedical engineer with both biomedical research and engineering training. He has previously worked and published in roles at the forefront of computational modelling, in-vitro modelling, immunology, and project management.

As a co-founder of Concr, Matt helped define and shape the company mission, and as a former CEO, he was instrumental in building and steering the company to significant  milestones. In his role as the Chief Innovation Officer, Matt will continue to apply his innovative thinking to new applications of Concr technology. 

As his first start-up, Matt takes the most pride in developing and being part of an environment to learn from the Concr team, seeing them find purpose in the company mission. His passion is to realise the vision of patient-centred and fully accessible precision diagnostics in oncology.

Emre Misirlioglu

Chief Operating Officer

As the generalist responsible for the smooth running of day-to-day activities, Emre embraces a versatile approach to leading the company operations at Concr. He is tasked with designing and implementing practical solutions for Concr’s key business objectives.

Together with the Executive Committee and alongside an expert team of advisors, Emre spearheads corporate development, quality management, regulatory compliance and GTM strategy implementation to deliver Concr's innovative solutions to market. With a clinical background and a commitment to elevating health and well-being at all levels, he is part of Concr’s translational efforts to connect cutting-edge technology with meaningful patient outcomes.

Barney Plummer

Head of Product Development

With a background in physics, Barney leads the product development efforts at Concr with a hands-on approach. An expert in healthcare software development, he has vast experience in a variety of projects including AI/ML work, database performance profiling, and mobile app development.

His current responsibilities in UX/UI and software development coupled with his past experience in building products used by thousands of clinicians are put to good use in placing Concr's technology in the hands of its users.

Careers

Help us enable biopharma, diagnostics and healthcare industries to discover better ways to overcome cancer.

Career opportunities

Partnerships

Our partners leverage Concr advanced predictive modelling across every stage of therapeutic development to create shared value for the benefit of cancer patients.

Partnerships

Investors

Our growth is powered by funding and hands-on support from across three continents.

Investors and funding